AGAbdelrahman Gad

Abdelrahman Gad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdelrahman Gad has a total of 161 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metabolite Relaxation Times at 3T From Birth to 7 Years

    by Saipavitra Murali-Manohar, Abdelrahman Gad, Zahra Shams, Gizeaddis L. Simegn, Yulu Song, Aaron T. Gudmundson, Helge J. Zo□Llner, Christopher W. Davies-Jenkins, Dunja Simicic, Vivek Yedavalli, et al.

    Purpose: With growing interest in pediatric MRS to understand the neurochemistry of brain development, it is essential to establish pediatric-specific metabolite T 1 and T 2 relaxation times for reliable quantification of metabolites. Furthermore, characterization of age-related changes in relaxation times may provide insight into developmental differences in tissue microstructure and cellular composition. Therefore, the goals of this study were two-fold: (1) to estimate metabolite T 1 and T 2 relaxation times in a pediatric cohort; and (2) to assess linear relationships between age and relaxation times. Methods: TI- and TE-series data were acquired from the bilateral thalamus in 20 and 25 participants aged between 0 and 7 years, respectively. Data were processed and modelled in Osprey 2.5.0. Metabolite T 1 and T 2 relaxation times of total N-acetylaspartate at 2.0 ppm (tNAA 2.0 ), total creatine at 3.0 ppm (tCr 3.0 ), total creatine at 3.9 ppm (tCr 3.9 ), total choline (tCho), myo-inositol (mI) and the combined glutamate and glutamine (Glx) were estimated by fitting the modelled signal amplitudes to TI-series inversion recovery signal and TE-series exponential decay equations, respectively. Linear relationships with age were tested for metabolite T 1 and T 2 relaxation times using Spearman correlations. Results: tNAA 2.0 and Glx showed significant changes in T 1 with age. tNAA 2.0 , tCr 3.0 , tCho and mI showed significant decrease in T 2 with age. Conclusion: Several metabolites showed significant changes in relaxation times with age in the thalamus region. Therefore, use of age-specific relaxation correction for pediatric studies using the linear equations provided is encouraged for reliable quantification of metabolites.

  • Open Access

    Age-related differences in neurometabolite concentrations during early infancy: A cross-sectional analysis of the HBCD Release 1.0

    by Saipavitra Murali-Manohar, Helge J. Zöllner, Christopher W. Davies-Jenkins, Aaron T. Gudmundson, Steve C. N. Hui, Yulu Song, Gizeaddis L. Simegn, Zahra Shams, Abdelrahman Gad, Borjan Gagoski, et al.

    Background: Developmental trajectories of low-concentration neurometabolites such as the neurotransmitter γ-aminobutyric acid (GABA), and the antioxidants glutathione (GSH) and ascorbate (Asc) across early infancy remain unexplored. Advances in spectral editing enabled the measurement of these key molecules together with high-concentration metabolites like N-acetylaspartate (NAA) and glutamate (Glu) in the HEALthy Brain and Child Development (HBCD) study, the largest longitudinal study of early brain development in the United States. Purpose: To determine the age-associated trajectories of 14 key neurometabolites during early infancy from a cross-sectional 1 H-MRS dataset. Materials and Methods: HBCD utilizes ISTHMUS, an integrated MRS sequence that includes both an unedited short-echo-time PRESS acquisition and an advanced 4-step Hadamard-encoded sequence, HERCULES to enable measurement of both high- and low-concentration metabolites. Metabolite quantification was carried out by the HBCD Data Coordinating Center (HDCC) using an automated Osprey pipeline, with data from 201 infants ages 0 – 10 weeks adjusted age included in the tabular imaging results in HBCD data release 1.0. After excluding preterm born infants and data with poor linewidth or model quality metric, we tested for linear associations with adjusted age for each metabolite. Results: Concentration estimates of total NAA (tNAA), total creatine (tCr) and glutamate (Glu) as well as the combined sum of glutamate and glutamine (Glx) significantly increased across ages 0 – 10 weeks, while myo-inositol (mI) decreased. GABA and GSH showed age-related trends, but did not reach significance. Levels of the lipid precursor phosphorylethanolamine (PE) and Asc are higher in the first months than established adult values. Conclusion: Multiple metabolites showed significant age-related changes during early infancy. While GABA and GSH did not, future work will establish whether the trends suggested here contribute to linear or non-linear patterns across the first years of life. Summary Statement: HBCD MRS Data Release 1.0 cross-sectional analysis of tabulated results shows significant changes of neurometabolite levels in the thalamus from birth to 10-week-old infants. Key Results: This study provides the first ever concentration level reports of multiple low-concentration metabolites such as GABA+, GSH, PE, Lac, Asc as well as their cross-sectional trajectory in early postnatal period of brain development.

  • Open Access

    Real-time AI integration for MR to detect artifacts and guide pulse sequence adaptations

    by Aaron T. Gudmundson, Zahra Shams, Abdelrahman Gad, Shuyuan Wang, Dunja Simicic, Saipavitra Murali-Manohar, Gizeaddis Lamesgin Simegn, Ipek Özdemir, Christopher W. Davies-Jenkins, Vivek Yedavalli, et al.

    This work presents a first-of-its-kind artificial intelligence (AI-)integrated MR pulse sequence that detects out-of-voxel (OOV) artifacts in real-time (within-TR) and responds prospectively by updating the crusher gradient scheme. Per Excitation Real-time Execution & Guided Responses with Integrated Neural-network Evaluation (PEREGRINE), allows for deployment of deep learning models and pulse sequence updates. In this study, PEREGRINE operated a time-domain (TD) and frequency-domain (FD) convolutional autoencoder that detect OOV artifacts. Scans without (AI-off) and with (AI-on) updates were collected from the medial prefrontal cortex of healthy volunteers using a MEGA-edited MRS experiment. The degree of OOV contamination (OOV Score) was quantified per transient based upon the prevalence of OOV signals in the TD and FD data. OOV Scores above a user-defined threshold triggered an update of the crusher gradient scheme, iterating through 48 permutations (6 axis transpositions × 8 polarity flips). Within each 2-second TR, PEREGRINE successfully provided single-transient OOV Scores and updated gradients accordingly. No difference was observed between the OOV Scores from the full (“Full” condition) AI-on and AI-off sessions due to the AI-on scan cycling over better and worse gradient permutations relative to the AI-off scan. However, the AI-on scan had significantly lower OOV Scores than the AI-off scan when selecting the transients where PEREGRINE persisted (“Dwell” condition) on a given gradient permutation. Ultimately, Fit Quality Number (FQN) from linear combination modeling improved significantly for the AI-on compared to the AI-off scan. PEREGRINE enabled an adaptive and AI-integrated sequence allowing for real-time evaluation and response to OOV artifacts, identifying gradient modifications that produced less OOV contamination. Graphical Graphical Abstract Summary: PEREGRINE, Per Excitation Real-time Execution & Guided Responses with Integrated Neural-network Evaluation, allows for pulse sequence updates using on-scanner deployed neural networks. To demonstrate the utility, PEREGRINE was used to operate two neural networks (time/frequency domain), trained to detect out-of-voxel artifacts, during a MEGA-edited MRS experiment in the prefrontal cortex. When artifacts were detected, PEREGRINE updated the crusher gradients within the same TR. Real-time, adaptive, and AI-driven MR will provide a long-awaited solution for combatting artifacts and poor data quality. Graphical Abstract Figure:

  • FDA‐Approved Drugs Containing D‐Amino Acids: A Historical and Developmental Perspective

    by Linh Tran, Tien Dung Nguyen, Abdelrahman Gamil Gad, Ethar Shaaban, Tu Ha Tai, Nguyen Thanh Tram, Huynh Nguyen Khanh Tran, Minh‐Tri Le, Nguyen Tien Huy

    D ‐Amino acids, the non‐natural enantiomers of l ‐amino acids, have emerged as powerful tools in peptide drug development due to their unique biochemical properties. Their resistance to proteolytic degradation, enhanced conformational rigidity, and reduced immunogenicity make them especially valuable in designing long‐acting and receptor‐selective therapeutics. Since the mid‐20th century, more than 20 FDA‐approved drugs have incorporated at least one d ‐amino acid into their structure, spanning indications from infectious diseases and endocrine disorders to rare dermatologic conditions and diagnostic imaging. These drugs include both natural products like gramicidin D and synthetic analogs such as desmopressin, leuprolide, bremelanotide, and etelcalcetide, the latter being the first fully d ‐amino acid peptide to receive FDA approval. This review traces the historical development and clinical adoption of d ‐amino acid‐containing drugs, highlighting their mechanisms of action, therapeutic relevance across disease areas, and the technological innovations, particularly solid‐phase peptide synthesis and conceptual advances such as mirror‐image phage display, that enabled their advancement. As peptide therapeutics continue to evolve, d ‐amino acids‐containing drugs are poised to play a central role in the next generation of targeted, stable, and high‐precision pharmaceuticals.

  • Measles Resurgence: Could a Third Vaccine Dose Be the Solution?

    by Huynh Tran Bao Chau, Bui Cong Minh, Jeza Muhamad Abdul Aziz, Hoang Bao Tran Van, Bui Nguyen Ha Tien, Abdelrahman Gad, Khanh Dang Nguyen, Pham Hong Gam, Javeria Hamraa, Le Thi Thuy Hang, et al.

    Measles remains a highly infectious viral disease and continues to pose a major global public health concern, with recurrent outbreaks occurring despite the implementation of effective vaccination strategies. This review examines multifactorial drivers of current measles outbreaks, summarises current recommendations for the standard two‐dose measles‐containing vaccine schedule, and evaluates emerging immunological evidence regarding the administration of a third dose. Some studies indicate that a third measles‐containing vaccine dose can result in an enhanced response for both humoral and cellular immune responses among individuals with declining antibody levels. However, existing evidence is largely derived from small, context‐specific studies and does not yet demonstrate durable clinical protection or population‐level impact on measles transmission. Consequently, the role of a routine third dose remains uncertain. In conclusion, addressing the multifactorial drivers of measles resurgence, including strengthening two‐dose vaccination coverage, reducing vaccine hesitancy, improving surveillance, and closing immunity gaps, remains the primary priority for measles control. A third dose may be considered as an investigational strategy, but further large‐scale epidemiologic and effectiveness data are needed before any policy implementation can be considered.


  • Open Access

    Regulatory alignment in FDA expedited pathways for infectious diseases: a decadal review with predictive modeling insights

    by Nguyen Thanh Tam, Ahmed M. Sayed, Mohammad Najm Dadam, Randa Elsheikh, Jeza Muhammad Abdul Aziz, Abdelrahman Gamil Gad, Thi Thu Hoai Nguyen, Phillip Tran, Zhilin Zhang, Norio Ohmagari, et al.

    Despite infectious diseases being a significant threat to global health, there are continuing concerns that regulatory authorities do not prioritize therapeutic strategies for infectious diseases with the same urgency as those for oncological or orphan diseases. This study aims to examine the differences in the productivity of drug development and approval procedures between non-infectious and infectious diseases, and to determine the utilization patterns of acceleration programs. All molecules and biologic products approved between January 1, 2015, and December 31, 2024 (N = 464) were subject to a cross-sectional study. Drugs@FDA, the Federal Register, and ClinicalTrials.gov were used as sources of data to establish median Clinical Development Time (CDT), Regulatory Approval Time (RAT), and cumulative Regulatory Review Time (RRT). Kruskal–Wallis tests were used to compare median values (interquartile range, IQR), and chi-square tests were used for proportions. Time-to-event differences were tested using Kaplan–Meier analyses with log-rank testing, and hazard ratios (HRs) were calculated using Cox proportional hazards models. Multivariable logistic regression with interaction terms was used to model Priority Review, Fast Track, Breakthrough Therapy, and Accelerated Approval, reporting adjusted odds ratios (aOR). Of 464 approvals, 65 (14.0%) targeted infectious diseases. Median CDT was 2.76 years (IQR 1.80–4.25) versus 3.46 years (IQR 2.59–4.66; p = 0.003), and median RRT was 3.54 years (IQR 2.58–5.03) versus 4.22 years (IQR 3.24–5.73; p = 0.006) for infectious and non‑infectious drugs, respectively. Nevertheless, infectious agents were approved 58% faster (HR = 1.58; 95% CI 1.15–2.16; p = 0.0047). Infectious disease products were more likely to receive Fast Track (OR = 4.49; 95% CI 2.39–8.70) and Priority Review (OR = 10.69; 95% CI 4.57–29.50) but less likely to obtain Breakthrough Therapy (OR = 0.42; 95% CI 0.28–0.63) or Accelerated Approval (OR = 0.12; 95% CI 0.016–0.56). Infectious disease treatments outpace non-infectious disease treatments in terms of drug development and approval timelines. Nevertheless, they are less frequently utilized in pathways like Accelerated Approval, which are scientifically less applicable to acute-disease endpoints. Therefore, policy reforms should focus on addressing the underlying economic and scientific barriers to anti-infective innovation.


  • Open Access

    Gradient scheme optimization for PRESS-localized edited MRS using weighted pathway suppression

    by Gizeaddis L. Simegn, Zahra Shams, Saipavitra Murali-Manohar, Dunja Simicic, Abdelrahman Gad, Yulu Song, Vivek Yedavalli, Christopher W. Davies-Jenkins, Aaron T. Gudmundson, Helge J. Zöllner, et al.

    This study aimed to design and implement an optimized gradient scheme for PRESS-localized edited magnetic resonance spectroscopy (MRS) to enhance suppression of out-of-voxel (OOV) artifacts. These artifacts, which originate from insufficient crushing of unwanted coherence transfer pathways (CTPs), are particularly challenging in editing schemes for metabolites like gamma-aminobutyric acid and glutathione. To address this, a volume-based likelihood model was developed to guide gradient scheme optimization, prioritizing suppression of CTPs based on likelihood. A volume-based likelihood model for CTP weighting was integrated into a Dephasing optimization through coherence order pathway selection (DOTCOPS) gradient optimization. Using a genetic algorithm with a new dual-penalty cost function, gradient schemes were optimized to maximize pathway-specific suppression. Hardware and sequence constraints, maximum gradient amplitudes and delay durations respectively, informed the optimization. Validation of the optimized scheme was performed with simulations by calculating the k-space crushing efficiency analytically with k-space trajectory. and in vivo using an edited MRS sequence in three brain regions (posterior cingulate cortex PCC, thalamus, and medial prefrontal cortex (mPFC)), with particular focus on OOV artifact reduction and spectral quality improvements. A three-way Analysis of Variance was used to assess the significance level of OOV artifact reduction. The optimized gradient scheme demonstrated improved k-space crushing efficiency (by an average of 197%). OOV artifacts were reduced in all brain regions, particularly in highly OOV-susceptible regions (thalamus and mPFC). Improvements were most notable around 4.3 ppm with significant OOV artifact amplitude reductions (p < 0.001). By using a volume-based likelihood model for CTP prioritization, the optimized DOTCOPS scheme ensures robust and region-agnostic performance in reducing OOV artifacts.

  • Open Access

    How to improve planetary health: Devising the ‘Planetary Health Approach’ from the biogeochemical flow perspectives

    by Yoshihiro Aoki, Ayumi Miyagi, Ayako Toyokawa, Shoko Misaka, Jin Yoshida, Abdelrahman M Makram, Abdelrahman Gamil Gad, Nguyen Tien Huy

    Planetary health is defined as ‘the health of human civilisation and the state of the natural systems on which it depends’ [1]; it is a relatively new concept and an unexplored field with little research in progress. It aims to provide and determine specific environmental limits to humanity within which they can safely operate. And […]

  • Open Access

    Awareness and preparedness of healthcare workers against the first wave of the COVID-19 pandemic: A cross-sectional survey across 57 countries

    by Nguyen Tien Huy, R. Matthew Chico, Vuong Thanh Huan, Hosam Waleed Shaikhkhalil, Vuong Ngoc Thao Uyen, Ahmad Taysir Atieh Qarawi, Shamael Thabit Mohammed Alhady, Nguyen Lam Vuong, Le Van Truong, Mai Ngoc Luu, et al.

    Background: Since the COVID-19 pandemic began, there have been concerns related to the preparedness of healthcare workers (HCWs). This study aimed to describe the level of awareness and preparedness of hospital HCWs at the time of the first wave. Methods: This multinational, multicenter, cross-sectional survey was conducted among hospital HCWs from February to May 2020. We used a hierarchical logistic regression multivariate analysis to adjust the influence of variables based on awareness and preparedness. We then used association rule mining to identify relationships between HCW confidence in handling suspected COVID-19 patients and prior COVID-19 case-management training. Results: We surveyed 24,653 HCWs from 371 hospitals across 57 countries and received 17,302 responses from 70.2% HCWs overall. The median COVID-19 preparedness score was 11.0 (interquartile range [IQR] = 6.0–14.0) and the median awareness score was 29.6 (IQR = 26.6–32.6). HCWs at COVID-19 designated facilities with previous outbreak experience, or HCWs who were trained for dealing with the SARS-CoV-2 outbreak, had significantly higher levels of preparedness and awareness (p<0.001). Association rule mining suggests that nurses and doctors who had a ’great-extent-of-confidence’ in handling suspected COVID-19 patients had participated in COVID-19 training courses. Male participants (mean difference = 0.34; 95% CI = 0.22, 0.46; p<0.001) and nurses (mean difference = 0.67; 95% CI = 0.53, 0.81; p<0.001) had higher preparedness scores compared to women participants and doctors. Interpretation: There was an unsurprising high level of awareness and preparedness among HCWs who participated in COVID-19 training courses. However, disparity existed along the lines of gender and type of HCW. It is unknown whether the difference in COVID-19 preparedness that we detected early in the pandemic may have translated into disproportionate SARS-CoV-2 burden of disease by gender or HCW type.


  • Open Access

    Clinical and laboratory factors associated with coronavirus disease 2019 (Covid‐19): A systematic review and meta‐analysis

    by Le Huu Nhat Minh, Ali Ahmed‐Fouad Abozaid, Nam Xuan Ha, Loc Le Quang, Abdelrahman Gamil Gad, Ranjit Tiwari, Tran Nhat‐Le, Dinh Kim Quyen, Balqees Al‐Manaseer, Nguyen Dang Kien, et al.

    Summary: SARS Coronavirus‐2 is one of the most widespread viruses globally during the 21st century, whose severity and ability to cause severe pneumonia and death vary. We performed a comprehensive systematic review of all studies that met our standardised criteria and then extracted data on the age, symptoms, and different treatments of Covid‐19 patients and the prognosis of this disease during follow‐up. Cases in this study were divided according to severity and death status and meta‐analysed separately using raw mean and single proportion methods. We included 171 complete studies including 62,909 confirmed cases of Covid‐19, of which 148 studies were meta‐analysed. Symptoms clearly emerged in an escalating manner from mild‐moderate symptoms, pneumonia, severe‐critical to the group of non‐survivors. Hypertension (Pooled proportion (PP): 0.48 [95% Confident interval (CI): 0.35–0.61]), diabetes (PP: 0.23 [95% CI: 0.16–0.33]) and smoking (PP: 0.12 [95% CI: 0.03–0.38]) were highest regarding pre‐infection comorbidities in the non‐survivor group. While acute respiratory distress syndrome (PP: 0.49 [95% CI: 0.29–0.78]), (PP: 0.63 [95% CI: 0.34–0.97]) remained one of the most common complications in the severe and death group respectively. Bilateral ground‐glass opacification (PP: 0.68 [95% CI: 0.59–0.75]) was the most visible radiological image. The mortality rates estimated (PP: 0.11 [95% CI: 0.06–0.19]), (PP: 0.03 [95% CI: 0.01–0.05]), and (PP: 0.01 [95% CI: 0–0.3]) in severe‐critical, pneumonia and mild‐moderate groups respectively. This study can serve as a high evidence guideline for different clinical presentations of Covid‐19, graded from mild to severe, and for special forms like pneumonia and death groups.